Role of Oral Factor Xa Inhibitors after Acute Coronary Syndrome

Sharma, Abhishek; Garg, Akash; Borer, Jeffrey S.; Krishnamoorthy, Parasuram; Garg, Jalaj; Lavie, Carl J.; Arbab‐Zadeh, Armin; Mukherjee, Debabrata; Ahmad, Hasan; Lichstein, Edgar

doi:10.1159/000368747

Cited by 10 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two factors (factor Xa and thrombin -factor II a) are involved in the process of clot formation. The thrombin production persists beyond acute presentation, and, consequently, antithrombin therapy, in addition to platelet inhibition, has been proposed [65][66][67]. Warfarin plus aspirin reduce the risk of ischaemic events after ACS with or without stenting when compared to aspirin alone.…”

Section: Areas Of Uncertainty Concerning Dat or Tat Regimens Post Procedures And Post Dischargementioning

confidence: 99%

Management of antithrombotic therapy in patients with atrial fibrillation and acute coronary syndromes

Pop¹,

Țînț²,

Petriş³

2021

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

If atrial fibrillation (AF) and acute coronary syndrome (ACS) coexist, they should be treated with combined antithrombotic therapy. To reduce the risk of bleeding while maintaining the desired antithrombotic effect, choices should be made for each patient according to the balance between the bleeding and the thrombotic risk. There are many ways to select the type and dose of the oral anticoagulant (OAC) and P2Y12 inhibitors. As a rule of thumb, aspirin and P2Y12 inhibitors should be recommended to all patients. The duration of this combination therapy is a matter of debate; available data promote an initial period of one to four weeks of triple antithrombotic association with aspirin and P2Y12 inhibitors (clopidogrel in the absence of high ischaemic risk) and preferable direct oral anticoagulants (DOACs). On discontinuing aspirin, double therapy with P2Y12 inhibitors and a DOAC provides similar efficacy and superior safety for many patients on ACS medical or interventional treatment, especially if the risk of bleeding is high and that of thrombosis is low. Further studies are needed to clarify the concerns for a slight augmentation in the number of ischaemic cases (myocardial infarction and stent thrombosis) with double antithrombotic regimen in patients at high ischaemic risk.

show abstract

Section: Areas Of Uncertainty Concerning Dat or Tat Regimens Post Procedures And Post Dischargementioning

confidence: 99%

Management of antithrombotic therapy in patients with atrial fibrillation and acute coronary syndromes

Pop¹,

Țînț²,

Petriş³

2021

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Apixaban also proved to be unprofitable in trials APPRAISE (Apixaban for Prevention of Acute Ischemic Events) and APPRAISE-2 and it has also been demonstrated that the concomitant use of anti-platelet drugs with these agents increases risk without benefit. ATLAS ACS 2-TIMI 46 and 52 investigated reduced doses of rivaroxaban and revealed its association with lower ischemic and bleeding risks, as well as a decrease in both stent thrombosis and mortality rates; therefore suggesting rivaroxaban to be a potential choice for anticoagulation in triple therapy in the future [68,[70][71][72].…”

Section: Stroke Prevention In Acute Coronary Syndromementioning

confidence: 99%

Stroke Prevention in Atrial Fibrillation

Karadi¹,

Lovadi²,

Csécsei³

et al. 2015

JCTCD

View full text Add to dashboard Cite

Stroke, as a complex, multidimensional cerebrovascular disease, is one of the key issues in the present day's healthcare. Recently, the emerging numbers of studies provide a wide range of future potential solutions in stroke care, implying an imminent change in the aspects of therapy. In this paper, we are going to give a brief insight into the most determinant aspects and factors of the disease, focusing on the very recent findings in research, as well as the practical approach in stroke prevention.

show abstract

“…Several recent studies have demonstrated the importance of factor Xa as a promising anticoagulant target, in addition to, the usage of many factor Xa inhibitors to prevent and treat a lot of thrombotic diseases [1][2][3][4][5][6] . The coagulation process involves proteins in coagulation reactions, which are called blood coagulation factors.…”

Section: Introductionmentioning

confidence: 99%

An in-Silico Study of Some Natural and Synthetic Compounds as Potential Inhibitors for Factor Xa

صباغ

AlBeik²,

Hadid³

2022

Bulletin of Pharmaceutical Sciences. Assiut

View full text Add to dashboard Cite

Recent research has demonstrated the significance of factor Xa and its inhibitors as a possible treatment approach. Since currently approved drugs have a wide variety of side effects, new anticoagulants must be developed. So, the goal of this in silico research is to find molecules that may act as factor Xa inhibitors. The structure of factor Xa (2w26) was obtained from the Protein Data Bank database, while the structures of the organic compounds were obtained from the ZINC database or via other means. In order to verify the anti-factor Xa action of these chemical compounds, iGemDock program was used to perform molecular docking. The compound ( 1) [5-hydroxy-2-(3-hydroxy-4-phenylmethoxyphenyl)-3,7bis(phenylmethoxy)chromen-4-one] showed the best interaction value against the 2w26 enzyme, and the binding energy was (-167.702 kcal/ mol); whereas the reference rivaroxaban was (-149.661 kcal/mol). These results lead to suggest new organic compounds as factor Xa inhibitors and further in vitro studies are required to confirm.

show abstract

Role of Oral Factor Xa Inhibitors after Acute Coronary Syndrome

Cited by 10 publications

References 51 publications

Management of antithrombotic therapy in patients with atrial fibrillation and acute coronary syndromes

Management of antithrombotic therapy in patients with atrial fibrillation and acute coronary syndromes

Stroke Prevention in Atrial Fibrillation

An in-Silico Study of Some Natural and Synthetic Compounds as Potential Inhibitors for Factor Xa

Contact Info

Product

Resources

About